Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Buy" by Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have received an average recommendation of "Buy" from the eight research firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $11.67.

A number of research firms have weighed in on ACRS. StockNews.com lowered shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Scotiabank began coverage on shares of Aclaris Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a research note on Tuesday, March 18th. They set an "overweight" rating for the company.

Aclaris Therapeutics Trading Up 1.5 %

NASDAQ:ACRS traded up $0.02 on Wednesday, reaching $1.36. 712,545 shares of the stock traded hands, compared to its average volume of 1,190,515. The company has a market capitalization of $147.26 million, a price-to-earnings ratio of -2.62 and a beta of 0.53. Aclaris Therapeutics has a 12 month low of $0.95 and a 12 month high of $5.17. The company's fifty day simple moving average is $1.54 and its 200 day simple moving average is $2.24.

Institutional Trading of Aclaris Therapeutics

Institutional investors have recently made changes to their positions in the stock. Cannon Global Investment Management LLC purchased a new position in shares of Aclaris Therapeutics in the first quarter worth approximately $57,000. Assenagon Asset Management S.A. boosted its holdings in shares of Aclaris Therapeutics by 71.5% in the first quarter. Assenagon Asset Management S.A. now owns 681,553 shares of the biotechnology company's stock worth $1,043,000 after buying an additional 284,191 shares during the last quarter. Jefferies Financial Group Inc. boosted its holdings in shares of Aclaris Therapeutics by 253.9% in the fourth quarter. Jefferies Financial Group Inc. now owns 40,700 shares of the biotechnology company's stock worth $101,000 after buying an additional 29,200 shares during the last quarter. Alpine Global Management LLC purchased a new position in shares of Aclaris Therapeutics in the fourth quarter worth approximately $38,000. Finally, Velan Capital Investment Management LP purchased a new position in shares of Aclaris Therapeutics in the fourth quarter worth approximately $67,000. Hedge funds and other institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.